基础医学与临床 ›› 2019, Vol. 39 ›› Issue (2): 277-280.

• 短篇综述 • 上一篇    下一篇

II型子宫内膜癌相关基因突变及靶向治疗研究进展

吴海芳1,孟祥玉2,许恒毅2,傅芬1   

  1. 1. 南昌大学第二附属医院
    2. 南昌大学青山湖校区食品科学与技术国家重点实验室
  • 收稿日期:2017-11-23 修回日期:2018-01-24 出版日期:2019-02-05 发布日期:2019-01-16
  • 通讯作者: 傅芬 E-mail:fu-fen@163.com
  • 基金资助:
    江西省科技计划

Research progress on gene mutations and targeted therapy of type II endometrial carcinoma

Hai-Fang WUXiang-Yu MENG2,Heng-Yi Xu2, 2   

  • Received:2017-11-23 Revised:2018-01-24 Online:2019-02-05 Published:2019-01-16

摘要: 子宫内膜癌是最常见的女性生殖系统肿瘤之一,其亚型非雌激素依赖型(II型)子宫内膜癌通常与P53基因突变和HER-2过量表达等基因异常相关。分子靶向治疗有望改善II型子宫内膜癌的治疗效果和预后情况。

关键词: Ⅱ型子宫内膜癌, 基因突变, 靶向治疗

Abstract: Endometrial carcinoma (EC) is one of the most commen gynecological cancer, Its subtype non-estrogen-dependent endometrial carcinoma (type II) is usually associated with gene abnormalities such as P53 gene mutation and HER-2 overexpression. Molecular targeted therapy may improve the therapeutic effect and prognosis of type II endometrial carcinoma.

Key words: Type II endometrial carcinoma, Gene mutation, Targeted therapy